Michael Bell is a Senior Director at Eli Lilly and Company, where they lead efforts in preclinical drug discovery and have over 30 years of experience in medicinal chemistry. Having served as a Principal Research Scientist at Eli Lilly from 1994 to 2022, Michael developed expertise in nuclear hormone receptors, enzymes, and GPCRs, while contributing to multiple patents and publications. Michael holds a BS in Chemistry from the University of Notre Dame and is currently pursuing further education in Organic Chemistry at Indiana University–Purdue University Indianapolis.
This person is not in the org chart
This person is not in any teams
This person is not in any offices